New long-lasting treatments for eye diseases
Official title: Novel Polymer-antibody Conjugates as Long-acting Therapeutics for Ocular Diseases
Funded at Delgen Biosciences INC. · NIH-10760186 · Data updated 2026-11-12
This study is looking at new ways to make eye treatments for wet age-related macular degeneration (AMD) last longer, so patients won't have to get injections as often, making it easier and safer for them to manage their condition.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Delgen Biosciences INC. NIH-funded |
| Lab location | 1 site (Chapel Hill, UNITED STATES) |
| Project start | September 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2023 |
| Award (this year) | $350,075 |
| NIH project number | 1R43EY034044-01A1 |
| Project ID | NIH-10760186 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with wet age-related macular degeneration.
✕Less likely to help
Patients with other forms of macular degeneration or those who do not have AMD may not benefit from this research.
What this research studies
This research focuses on developing innovative polymer-antibody conjugates aimed at treating wet age-related macular degeneration (AMD), a leading cause of blindness. The approach seeks to create long-acting formulations of existing anti-VEGF therapies, which currently require frequent injections. By improving drug delivery systems, the research aims to enhance the stability and effectiveness of these treatments, potentially reducing the need for regular administration. Patients may benefit from a more convenient and safer treatment option that could lead to better adherence and outcomes.
Why it matters
Potential benefit: If successful, this research could provide patients with a more effective and less burdensome treatment for wet AMD.
How similar studies have gone: Other research has shown promise in developing long-acting biologics, indicating potential success for this novel approach.
Where this research is happening
-
Delgen Biosciences INC.
Chapel Hill, United States Active
Researchers
- Principal investigator: Peng, Fei — Delgen Biosciences INC.
- Study coordinator: Peng, Fei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.